Barclays Lowers 10x Genomics (NASDAQ:TXG) Price Target to $18.00

10x Genomics (NASDAQ:TXG) had its target price decreased by equities research analysts at Barclays from $19.00 to $18.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Barclays‘s target price would suggest a potential upside of 26.32% from the stock’s current price.

A number of other equities research analysts have also recently weighed in on the company. Weiss Ratings restated a “sell (e+)” rating on shares of 10x Genomics in a research note on Saturday, February 1st. Morgan Stanley decreased their price target on shares of 10x Genomics from $30.00 to $28.00 and set an “overweight” rating for the company in a research report on Monday, January 13th. Citigroup cut their price objective on shares of 10x Genomics from $35.00 to $23.00 and set a “buy” rating on the stock in a research report on Wednesday, October 30th. JPMorgan Chase & Co. decreased their target price on shares of 10x Genomics from $20.00 to $14.00 and set a “neutral” rating for the company in a research report on Wednesday, October 30th. Finally, The Goldman Sachs Group cut their price target on shares of 10x Genomics from $16.00 to $14.00 and set a “sell” rating on the stock in a report on Wednesday, October 30th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $23.79.

10x Genomics Stock Down 2.7 %

10x Genomics stock opened at $14.25 on Monday. The firm has a market cap of $1.72 billion, a P/E ratio of -9.31 and a beta of 1.85. The business has a fifty day moving average of $15.06 and a two-hundred day moving average of $17.62. 10x Genomics has a twelve month low of $12.95 and a twelve month high of $51.22.

Institutional Trading of 10x Genomics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Assenagon Asset Management S.A. purchased a new position in shares of 10x Genomics during the fourth quarter worth $26,308,000. ARK Investment Management LLC raised its stake in shares of 10x Genomics by 15.4% during the 3rd quarter. ARK Investment Management LLC now owns 10,750,345 shares of the company’s stock valued at $242,743,000 after buying an additional 1,436,582 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in shares of 10x Genomics in the 3rd quarter valued at about $27,778,000. SVB Wealth LLC acquired a new position in shares of 10x Genomics in the 4th quarter valued at about $7,505,000. Finally, FMR LLC boosted its stake in shares of 10x Genomics by 2.7% in the third quarter. FMR LLC now owns 13,367,979 shares of the company’s stock worth $301,849,000 after buying an additional 357,470 shares during the last quarter. 84.68% of the stock is currently owned by institutional investors and hedge funds.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.